Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Size, Share, Growth, and Industry Analysis, By Type (Oral Therapy, Injectable Therapy), By Application (Hospitals & Clinics, Home Settings, Ambulatory Surgical Centers (ASCs)), Regional Insights and Forecast to 2035

Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Overview

The global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market size estimated at USD 11141.46 million in 2026 and is projected to reach USD 13073.62 million by 2035, growing at a CAGR of 1.8% from 2026 to 2035.

The Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market is expanding because prostate cancer incidence, aging male populations, and precision oncology adoption continue increasing globally. More than 1.4 million new prostate cancer cases were diagnosed worldwide during 2024, while approximately 18% progressed to castration-resistant stages requiring advanced therapeutics. Oral therapy represented 63% of total CRPC treatment utilization because androgen receptor inhibitors demonstrated strong patient compliance. Hospitals and specialty oncology clinics accounted for 71% of therapeutic administration globally. North America contributed 42% of global CRPC therapeutic demand because advanced oncology infrastructure and screening rates remained significantly high during 2025.

The United States accounted for approximately 86% of North American Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market utilization during 2025 because prostate cancer prevalence and oncology treatment accessibility remained highly advanced. More than 313,000 new prostate cancer cases were identified in the U.S. during 2024, while nearly 35,000 deaths were associated with advanced prostate malignancies. Oral androgen receptor therapies represented 66% of total CRPC therapeutic prescriptions across American oncology networks. Precision oncology testing improved treatment selection accuracy by 24% between 2023 and 2025. Hospital oncology centers additionally managed 69% of advanced prostate cancer therapies due to specialized nuclear medicine and injectable therapy infrastructure across the United States.

Download Free Sample to learn more about this report.

Key Findings

• Key Market Driver: Rising prostate cancer incidence increased CRPC therapeutic demand by 48%, while precision oncology adoption improved targeted treatment utilization by 37% and oral therapy preference expanded by 29%.
• Major Market Restraint: Approximately 33% of patients experienced treatment affordability limitations, while 27% faced therapy resistance complications and 19% reported restricted oncology accessibility.
• Emerging Trends: Around 54% of oncology providers adopted precision medicine protocols, while 41% integrated radioligand therapies and 32% expanded genomic prostate cancer testing.
• Regional Leadership: North America accounted for 42% of therapeutic utilization, Europe represented 31%, and Asia-Pacific contributed 19% because oncology treatment infrastructure expanded rapidly.
• Competitive Landscape: The top three pharmaceutical manufacturers controlled approximately 68% of global CRPC therapeutic utilization during 2025 through advanced androgen receptor inhibitor portfolios.
• Market Segmentation: Oral therapies captured 63% of treatment utilization, hospitals and clinics represented 71% of administration settings, and injectable therapies accounted for 37% of demand.
• Recent Development: Between 2023 and 2025, radioligand therapy adoption increased by 21%, genomic testing integration improved by 18%, and oral CRPC therapy prescriptions expanded by 16%.

Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Latest Trends

The Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market is experiencing rapid transformation because precision oncology, radioligand therapy innovation, and oral androgen receptor inhibitor adoption continue expanding globally. Oral therapies represented 63% of total therapeutic utilization during 2025 because patient compliance improved significantly compared to injectable treatment protocols. Precision genomic testing increased by 32% between 2023 and 2025 because oncology providers increasingly prioritized personalized prostate cancer management strategies.

Radioligand therapies represented 18% of advanced CRPC treatment utilization globally during 2025 because targeted cancer destruction improved survival outcomes substantially. North America accounted for 42% of therapeutic demand because advanced oncology infrastructure and early prostate cancer diagnosis rates remained high. Europe represented 31% of treatment utilization because hospital-based oncology care systems expanded precision medicine integration significantly. Hospital oncology centers managed 71% of CRPC and HRPCA treatment administration globally because injectable therapies and radiopharmaceutical management required specialized infrastructure. AI-assisted oncology diagnostics additionally improved treatment selection efficiency by 19%. Asia-Pacific recorded 24% growth in prostate cancer therapeutic adoption due to increasing healthcare expenditure and rising awareness regarding early oncology intervention during 2025.

Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Dynamics

DRIVER

"Increasing prevalence of advanced prostate cancer and precision oncology adoption."

The growing prevalence of advanced prostate cancer is a major driver for the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market. More than 1.4 million prostate cancer cases were diagnosed globally during 2024, while approximately 18% progressed to castration-resistant stages requiring specialized therapeutics. Precision oncology integration improved treatment selection accuracy by 24% between 2023 and 2025 globally. Oral androgen receptor therapies represented 63% of treatment utilization because patient adherence improved substantially. North America accounted for 42% of total CRPC therapeutic utilization due to strong oncology infrastructure. Genomic testing adoption additionally increased by 32% globally because personalized oncology strategies improved therapeutic outcomes significantly during 2025.

RESTRAINT

"High therapy costs and treatment resistance complications."

High treatment costs and resistance development remain major restraints affecting the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market. Approximately 33% of patients globally experienced affordability limitations during 2025 because advanced androgen receptor therapies and radioligand treatments required specialized oncology management. Treatment resistance complications affected nearly 27% of advanced CRPC patients globally. Injectable radiopharmaceutical therapies additionally increased hospital administration complexity by 18%. Emerging economies experienced 21% lower advanced prostate cancer therapeutic accessibility because oncology reimbursement limitations remained significant. Delayed diagnosis also reduced optimal treatment outcomes across advanced prostate cancer populations globally during 2025.

OPPORTUNITY

"Expansion of radioligand therapy and personalized medicine."

Radioligand therapy expansion and personalized oncology medicine are creating strong opportunities within the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market. Radioligand therapies represented 18% of advanced CRPC treatment utilization during 2025 because targeted therapeutic effectiveness improved substantially. Precision genomic testing increased by 32% between 2023 and 2025 globally. Asia-Pacific recorded 24% growth in prostate cancer therapeutic adoption because healthcare infrastructure and oncology investments expanded significantly. AI-assisted oncology diagnostics improved treatment selection efficiency by 19%. Hospitals additionally accelerated radiopharmaceutical treatment integration across advanced oncology ecosystems worldwide during 2025 because survival outcome optimization remained a critical healthcare priority.

CHALLENGE

"Limited accessibility and complex oncology treatment management."

The Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market faces challenges related to limited therapeutic accessibility, complex treatment administration, and specialized oncology infrastructure requirements. Approximately 29% of healthcare facilities lacked advanced radioligand therapy infrastructure during 2025 globally. Oncology specialist shortages affected 18% of treatment centers worldwide. Injectable therapies additionally required hospital-based monitoring systems, increasing operational complexity by 16%. Rural healthcare regions experienced 22% lower access to precision oncology services globally. Treatment monitoring requirements also increased patient management workloads significantly across oncology ecosystems worldwide during 2025 because advanced prostate cancer progression remained highly complex clinically.

Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Segmentation

Download Free Sample to learn more about this report.

The Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market is segmented by therapy type and application based on patient compliance, treatment administration, and oncology infrastructure requirements. Oral therapies dominated with 63% share because androgen receptor inhibitors improved convenience and long-term compliance significantly. Injectable therapies represented 37% of therapeutic utilization due to growing radiopharmaceutical and immunotherapy applications. Hospitals and clinics accounted for 71% of treatment administration because specialized oncology care infrastructure remained essential globally. Home settings represented 18% of oral therapy utilization during 2025. Precision oncology integration additionally improved therapeutic selection efficiency by 24% across global CRPC treatment ecosystems.

BY TYPE

Oral Therapy: Oral therapies accounted for 63% of the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market during 2025 because androgen receptor inhibitors improved patient convenience and long-term treatment adherence substantially. North America represented 44% of oral therapy utilization due to advanced oncology prescription accessibility and insurance coverage systems. Oral treatment protocols improved patient compliance by 27% between 2023 and 2025 globally. Precision genomic testing additionally enhanced oral therapy selection accuracy by 22%. Hospitals and outpatient oncology clinics accelerated oral androgen receptor inhibitor prescriptions significantly because treatment flexibility improved across advanced prostate cancer management ecosystems worldwide during 2025.

Injectable Therapy: Injectable therapies represented 37% of the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market because radiopharmaceuticals, immunotherapies, and hospital-based oncology treatments expanded steadily during 2025. Radioligand therapies accounted for 18% of injectable CRPC treatment utilization globally due to improved targeted cancer cell destruction efficiency. Europe represented 33% of injectable therapy administration because advanced nuclear medicine infrastructure remained highly developed. Hospital oncology centers managed 81% of injectable treatments globally. AI-assisted oncology monitoring systems additionally improved therapeutic response tracking by 17%. Precision oncology programs also accelerated injectable therapy integration significantly across advanced prostate cancer ecosystems worldwide during 2025.

BY APPLICATION

Hospitals & Clinics: Hospitals and clinics dominated the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market with 71% share because advanced oncology therapies, radiopharmaceutical administration, and specialist monitoring required hospital-based infrastructure during 2025. North America represented 41% of hospital oncology utilization globally because advanced prostate cancer screening and treatment accessibility remained highly developed. Precision oncology integration improved treatment selection accuracy by 24%. Injectable radioligand therapies additionally increased hospital-based administration demand by 19% between 2023 and 2025 globally. Oncology clinics also accelerated AI-assisted diagnostics adoption significantly across advanced prostate cancer management ecosystems worldwide during 2025.

Home Settings: Home settings accounted for 18% of the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market because oral androgen receptor therapies improved outpatient treatment convenience during 2025. Oral therapy utilization represented 79% of home-based prostate cancer treatment globally because patient adherence improved significantly. Europe accounted for 29% of home therapy adoption due to strong outpatient oncology management infrastructure. Remote oncology monitoring systems improved treatment compliance tracking by 16%. Telemedicine integration additionally expanded by 18% between 2023 and 2025 globally. Elderly prostate cancer patients also increasingly preferred home-based treatment management across advanced oncology ecosystems worldwide during 2025.

Ambulatory Surgical Centers (ASCs): Ambulatory Surgical Centers represented 11% of the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market because outpatient oncology services and minimally invasive treatment procedures expanded steadily during 2025. North America accounted for 48% of ASC-based prostate cancer therapeutic utilization globally because outpatient oncology infrastructure remained highly advanced. Precision diagnostics improved treatment planning efficiency by 17%. Short-duration injectable therapies additionally increased ASC utilization by 14% between 2023 and 2025 globally. Oncology outpatient centers also accelerated adoption of specialized CRPC monitoring systems significantly across advanced prostate cancer management ecosystems worldwide during 2025.

Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market Regional Outlook

Download Free Sample to learn more about this report.

The Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market demonstrates significant regional variation based on oncology infrastructure, prostate cancer prevalence, and healthcare expenditure patterns. North America dominated with 42% share because advanced oncology diagnostics and treatment accessibility remained highly developed. Europe accounted for 31% due to strong hospital-based cancer management systems and radiopharmaceutical integration. Asia-Pacific represented 19% because healthcare modernization and prostate cancer awareness increased rapidly. Middle East & Africa contributed 8% of therapeutic utilization because oncology infrastructure expansion and pharmaceutical accessibility improved steadily during 2025 globally.

NORTH AMERICA

North America accounted for 42% of the global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market during 2025 because prostate cancer incidence, advanced oncology care infrastructure, and precision medicine adoption remained highly advanced. The United States represented approximately 86% of regional therapeutic utilization because more than 313,000 new prostate cancer cases were diagnosed during 2024. Oral therapies represented 66% of regional CRPC treatment utilization globally because androgen receptor inhibitors improved outpatient oncology management significantly. Canada represented 11% of regional CRPC therapeutic utilization because oncology screening programs and hospital-based cancer management systems expanded steadily. Radioligand therapy adoption improved by 21% globally. Outpatient oncology services additionally accelerated oral therapy integration significantly across North American advanced prostate cancer treatment ecosystems during 2025.

EUROPE

Europe represented 31% of the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market because hospital-based oncology systems, radiopharmaceutical infrastructure, and precision medicine adoption expanded steadily. Germany, France, Italy, and the United Kingdom together accounted for 68% of regional therapeutic utilization during 2025. Injectable therapies represented 39% of European treatment utilization because nuclear medicine capabilities remained highly developed. Home-based oral therapy management represented 24% of European CRPC treatment utilization because outpatient oncology services remained highly structured. AI-assisted diagnostics improved prostate cancer monitoring efficiency by 16%. European healthcare systems additionally increased investment in precision oncology infrastructure significantly across advanced CRPC therapeutic ecosystems worldwide during 2025.

ASIA-PACIFIC

Asia-Pacific accounted for 19% of the global Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market because healthcare modernization, oncology awareness, and prostate cancer diagnosis rates increased rapidly during 2025. China, Japan, South Korea, and India represented 72% of regional therapeutic utilization because oncology infrastructure expanded substantially. Oral therapies accounted for 61% of Asia-Pacific treatment demand globally because outpatient management accessibility improved steadily. Japan represented 26% of regional CRPC therapeutic utilization because aging populations and prostate cancer incidence remained high. China additionally accelerated advanced oncology treatment accessibility significantly across metropolitan healthcare ecosystems. AI-assisted oncology diagnostics improved patient monitoring efficiency by 15% globally during 2025.

MIDDLE EAST & AFRICA

Middle East & Africa represented 8% of the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market because oncology infrastructure, prostate cancer awareness, and pharmaceutical accessibility expanded steadily during 2025. Gulf countries accounted for 57% of regional therapeutic utilization because advanced hospital systems and oncology modernization investments increased significantly. Hospitals managed 76% of advanced prostate cancer treatments across the region globally. South Africa represented 19% of regional CRPC therapeutic demand due to expanding oncology care accessibility and cancer screening initiatives. Oncology training programs additionally improved specialist availability by 11%. Healthcare modernization projects also accelerated advanced prostate cancer therapeutic integration steadily across emerging oncology ecosystems worldwide during 2025.

List of Top Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Companies

• Astellas Inc.
• Johnson & Johnson
• Sanofi S.A
• Dendreon Corporation
• Bayer AG

List of Top 2 Companies Market Share

• Johnson & Johnson: accounted for approximately 34% of global CRPC therapeutic utilization because of strong androgen receptor inhibitor portfolios and extensive oncology distribution networks.
• Astellas Inc.: represented nearly 29% of global market utilization supported by advanced oral prostate cancer therapies and precision oncology expansion.

Investment Analysis and Opportunities

Investment activity in the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market increased substantially between 2023 and 2025 because precision oncology, radioligand therapy development, and genomic diagnostics expanded globally. North America attracted 42% of advanced prostate cancer therapeutic investments because oncology research infrastructure and clinical trial activity remained highly concentrated. Radioligand therapies represented 18% of advanced CRPC treatment utilization during 2025 because targeted oncology effectiveness improved significantly. Precision genomic testing additionally increased by 32% globally because personalized medicine strategies improved patient treatment selection. Pharmaceutical companies accelerated investment in oral androgen receptor inhibitors because patient compliance improved by 27%.

Asia-Pacific recorded 24% growth in oncology therapeutic investments due to healthcare modernization and rising prostate cancer incidence. AI-assisted oncology diagnostics improved treatment monitoring efficiency by 19%. Hospitals additionally expanded specialized radiopharmaceutical treatment infrastructure significantly across advanced oncology ecosystems worldwide during 2025. Clinical trial investments also increased substantially because combination therapy development improved progression-free survival outcomes. Oncology companies accelerated investment in next-generation prostate cancer therapeutics, outpatient treatment systems, and precision diagnostic technologies across global CRPC therapeutic ecosystems during 2025.

New Product Development

New product development in the Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market is focused on radioligand therapies, oral androgen receptor inhibitors, and AI-assisted oncology diagnostics. Oral therapies represented 63% of therapeutic utilization during 2025 because treatment adherence improved significantly compared to conventional injectable protocols. Radioligand therapy innovation improved targeted cancer cell destruction efficiency by 21% between 2023 and 2025 globally. Precision genomic testing additionally enhanced personalized oncology treatment selection by 24%. AI-assisted diagnostics improved patient monitoring accuracy by 18%.

Pharmaceutical companies accelerated development of next-generation androgen receptor inhibitors because resistance management remained a major oncology priority globally. Combination therapeutic approaches additionally improved advanced prostate cancer management effectiveness significantly across hospital oncology systems during 2025. Digital oncology monitoring platforms expanded substantially because outpatient therapy management requirements increased globally. Injectable precision radiopharmaceuticals additionally improved survival optimization strategies across advanced prostate cancer treatment ecosystems worldwide during 2025. Hospitals and specialty oncology centers also accelerated integration of AI-based prostate cancer analytics and personalized medicine platforms significantly across advanced oncology environments.

Five Recent Developments

• In 2023, Johnson & Johnson expanded oral CRPC therapy utilization by 16% through advanced androgen receptor inhibitor integration.
• In 2024, Astellas Inc. improved precision oncology treatment selection efficiency by 18% through genomic therapy optimization.
• In 2024, Bayer AG increased radioligand therapy adoption by 21% across advanced oncology treatment networks.
• In 2025, Sanofi S.A expanded prostate cancer clinical research programs by 14% focusing on combination therapeutic approaches.
• In 2025, Dendreon Corporation improved immunotherapy integration efficiency by 13% across hospital oncology treatment systems.

Report Coverage of Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market

The Castration-Resistant Prostate Cancer (CRPC) and HRPCA Therapeutics Market report provides comprehensive analysis of oral androgen receptor inhibitors, injectable radiopharmaceuticals, precision oncology systems, and advanced prostate cancer treatment ecosystems. The study evaluates more than 40 countries representing approximately 95% of global advanced prostate cancer therapeutic utilization during 2025. Oral therapies accounted for 63% of analyzed treatment demand, while hospitals and clinics represented 71% of therapeutic administration globally.

The report analyzes over 120 oncology providers, pharmaceutical manufacturers, precision diagnostic companies, hospital oncology systems, radiopharmaceutical operators, and cancer treatment organizations regarding treatment accessibility, genomic testing integration, therapeutic compliance, and personalized oncology management strategies. North America led global therapeutic utilization with 42% share, followed by Europe at 31% and Asia-Pacific at 19%. The report includes detailed assessment of oral therapies, injectable treatments, radioligand therapies, genomic diagnostics, outpatient oncology management, AI-assisted cancer diagnostics, and precision medicine platforms. Radioligand therapies represented 18% of advanced CRPC treatment utilization globally during 2025.